Intervacc AB (publ) Share Price Nasdaq Stockholm
Equities
SE0009607252
Biotechnology & Medical Research
Sales 2024 * | 19.2M 1.78M 148M | Sales 2025 * | 53.1M 4.91M 410M | Capitalization | 329M 30.41M 2.54B |
---|---|---|---|---|---|
Net income 2024 * | -77M -7.12M -594M | Net income 2025 * | -66M -6.11M -509M | EV / Sales 2024 * | 11.1 x |
Net cash position 2024 * | 116M 10.73M 895M | Net cash position 2025 * | 55M 5.09M 424M | EV / Sales 2025 * | 5.15 x |
P/E ratio 2024 * |
-4.25
x | P/E ratio 2025 * |
-4.99
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.16% |
Managers | Title | Age | Since |
---|---|---|---|
Jonas Sohlman
CEO | Chief Executive Officer | - | 21/23/21 |
Jan Persson
DFI | Director of Finance/CFO | - | 06/20/06 |
Andrew Waller
CTO | Chief Tech/Sci/R&D Officer | - | 11/20/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Boel Sundvall
BRD | Director/Board Member | 65 | 01/23/01 |
Chairman | 56 | - | |
Edwin Torr
BRD | Director/Board Member | 63 | - |
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |